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Abstract
Health issue: Cervical cancer is one of the most common malignant diseases of women; it is
diagnosed in almost half a million women every year and half as many die from it annually. In Canada
and other industrialized countries, its incidence has decreased due to cytology screening. However,
invasive cases still occur, particularly among immigrant groups and native Canadian women.
Although incidence of squamous cell carcinomas has decreased, the proportion of
adenocarcinomas has increased because Pap cytology is ineffective to detect these lesions.
Key findings: In Canada, cervical cancer will cause an estimated 11,000 person-years of life lost.
In most Canadian provinces, early detection is dependent on opportunistic screening. Primary
prevention can be achieved through health education (sexual behavior modification) and
vaccination to prevent infection from Human Papillomavirus (HPV). The initial results from
vaccination trials are encouraging but wide scale use is more than a decade away.
Data gaps and recommendations: Most cases of cervical cancer occur because the Pap smear
was either false negative, was not done or not done often enough. Appropriate recommendations
and guidelines exist on implementation of cytology-based programs. However, most Canadian
women do not have access to organized screening. Further research is needed to 1) evaluate
automated cytology systems; 2) define appropriate management of precursor lesions and 3) deliver
definitive evidence of HPV testing efficacy in long-term follow-up studies with invasive cancer as an
outcome and 4) provide Canadian data to justify augmenting or modifying current programs to use
HPV testing in secondary triage of equivocal Pap smears.
Background
Cervical cancer is a malignant neoplastic disease that
tends to begin slowly when there is a disruption of the cer-
vical epithelium, near the squamocolumnar junction of
the uterine cervix. Initially, this pre-invasive process is
limited to the cervical epithelium and is known variably
as cervical intraepithelial neoplasia (CIN), according to
the classification scheme mostly used in histopathology,
or as squamous intraepithelial lesion (SIL), as per the clas-
sification system favoured for cytopathological diagnosis.
Low-grade SIL (LSIL) (equivalent to CIN 1) and high-
grade SIL (HSIL, equivalent to CIN 2 and 3) are invariably
asymptomatic and can be detected through cytological
examination using the Papanicolaou technique (the Pap
test). Their presence is confirmed by magnification during
colposcopic examination and by biopsy. If left untreated,
LSIL may become HSIL, and the latter may eventually
extend to the full thickness of the cervical epithelium, a
condition that is recognized as cervical carcinoma in situ
(CIS).
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Subsequently, the disease may become invasive. This
process may take a decade or longer. There are two main
histological types of invasive cancer: squamous cell carci-
nomas and adenocarcinomas. The invasive lesion may
metastasize to nearby pelvic and distant lymph nodes and
other body sites. The symptoms and signs in most women
with invasive cervical cancer include post-coital bleeding,
recurrent bladder infections and ulcers on the cervix. Pres-
sure against nerve trunks and the sacral plexus produces
persistent pain. As soon as lymph node metastasis occurs
the disease worsens considerably.
The women most at risk of this disease in North America
are Native populations, Black women, the Hispanic pop-
ulation and recent immigrant groups. Screening programs
may not be reaching these women, and when cervical can-
cer is eventually diagnosed there may be barriers in the
way of speedy access to the most recent and effective treat-
ment methods. Women of low socio-economic status also
face a less favourable outcome.
Methods
Data on incidence rates and rates of mortality from cervi-
cal cancer in Canada were obtained from Statistics Canada
and the Ministère de la santé et des services sociaux du
Québec, and in the United States from the Surveillance,
Epidemiology, and End Results (SEER) Program. Other
epidemiologic and risk factor information was found in
published surveillance and research reports.
Results
Cervical Cancer in Canada
Canada has been a pioneer among Western countries in
adopting wide-scale cervical cancer screening with the Pap
test, and this has greatly contributed to its current status as
a country with one of the lowest incidence rates of the dis-
ease worldwide. Cervical cancer is expected to be newly
diagnosed in an estimated 1,400 Canadian women in
2003 and will claim approximately 420 lives in that
period.[1]
Incidence and Mortality
Figure 1 shows the annual incidence and mortality rates of
cervical cancer (averages for the latest five-year reporting
period of 1994–1998) for Canada, for all Canadian prov-
inces, and for the United States, as a comparison. The
provinces with the highest incidence were Nova Scotia,
Newfoundland and Labrador and P.E.I., with rates exceed-
ing 10 per 100,000 women; Nova Scotia and Newfound-
land and Labrador also showed the highest mortality rates
among the provinces. Quebec and British Columbia had
the lowest incidence rates. Saskatchewan and Quebec
were the only two provinces with mortality rates below 2
per 100,000 per year.
Changes Over Time
As a general rule, incidence and mortality rates of cervical
cancer have declined in North America during the last 50
years in consequence of the increased availability of Pap
smear screening programs and probably also the decline
in fertility rates during the last half-century. Figure 2
shows the time trends in age-standardized incidence and
mortality of invasive cervical cancer for Canada and for
the United States since 1969. Although in the last 10 years
incidence rates have been very similar between the two
countries, Canadian women have a slight, yet consistent,
advantage over their U.S. counterparts with respect to
mortality from cervical cancer.
The decline in incidence has varied by province, as shown
in Figure 3. Some of the most dramatic decreases were
seen in the Atlantic provinces, in particular Nova Scotia
and P.E.I. The decrease in rates is not as pronounced in
provinces such as Saskatchewan and Alberta, which have
had the benefit of low cervical cancer rates during most of
the last 30 years. Although the range of rates among prov-
inces in 1969–1973 was wide (13 to 30 per 100,000), the
differences have levelled off to 7.6–11.2 per 100,000 in
the most recent five-year period of 1994–1998.
Average (Period 1994–1998), Annual Age-Standardized Inci- dence and Mortality Rates of Invasive Cervical Cancer for  Individual Canadian Provinces, for Canada, and for the  United States All rates refer to numbers of new cases or  deaths per 100,000 and are standardized according to the  Canadian population of 1991 Figure 1
Average (Period 1994–1998), Annual Age-Standardized Inci-
dence and Mortality Rates of Invasive Cervical Cancer for 
Individual Canadian Provinces, for Canada, and for the 
United States All rates refer to numbers of new cases or 
deaths per 100,000 and are standardized according to the 
Canadian population of 1991. Incidence data for the U.S. 
refer to the nine main state or metropolitan area registries 
belonging to the Surveillance, Epidemiology, and End Results 
(SEER) Program from the Cancer Surveillance Research Pro-
gram of the U.S. National Cancer Institute (NCI), and mor-
tality data refer to the entire U.S.population. Source: 
Statistics Canada and SEER database.[4]BMC Women's Health 2004, 4:S13 http://www.biomedcentral.com/1472-6874/4/S1/S13
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The decline in cervical cancer incidence in Canada can be
further examined by comparing age-specific rates by suc-
cessive five-year periods (Figure 4). The reduction in inci-
dence in the late 1960s and early 1970s was most
pronounced among women between the ages of 45 and
65. With successive periods, the net reduction shifted to
older women. Two incidence peaks have emerged since
the mid-1980s, one in women 35 to 44 years of age and
another in women aged 75 and over. The first peak seems
to be shifting to younger ages, possibly as a consequence
of increased opportunity for early diagnosis even among
invasive cancer cases. Since cervical cancer is linked to
multiple sexual partners, one cannot rule out the possible
contribution of a cohort effect due to the major changes
in social mores that began to occur in the late 1960s and
that led to increased opportunities for exposure to human
papillomavirus (HPV) infection at an early age (see "The
Role of HPV" below).
Most cervical cancers are squamous cell carcinomas.
While the decline of cervical cancer incidence applies to
this histological type, adenocarcinomas have actually
increased in incidence over the last 30 years in most West-
ern countries. The latter used to account for about 5% of
all invasive cervical cancers in the early 1970s and now
constitute approximately 20% of all such neoplasms.
The Global Burden of Cervical Cancer
Cervical cancer is one of the most common malignant dis-
eases of women. An estimated 471,000 new cases of inva-
sive cervical carcinoma are diagnosed annually
worldwide, with a disproportionately heavy burden of the
disease (380,000 new cases) occurring in developing
countries. In 2000 there were an estimated 233,000
deaths from cervical cancer worldwide.[2] Its worldwide
incidence represents nearly 10% of all female cancers, and
it is the third most common anatomic location among
women, afterbreast and colorectal cancer.[3] The highest
risk areas are in Central and South America, southern and
eastern Africa, and the Caribbean, where average
Trends in Incidence and Mortality Rates for Invasive Cervical  Cancer for Canada (Since 1969) and for the United States  (Since 1973) Figure 2
Trends in Incidence and Mortality Rates for Invasive Cervical 
Cancer for Canada (Since 1969) and for the United States 
(Since 1973). Rates are per 100,000 and are standardized 
according to the Canadian population of 1991. Incidence data 
for the United States refer to the nine main SEER registries 
and mortality data refer to the entire U.S. population. 
Source: Statistics Canada and SEER database.[4]
Trends in Incidence Rates for Invasive Cervical Cancer for  CanadianProvinces Rates are standardized according to the  Canadian population of 1991 and are presented as annual  averages (per 100,000) for successive five-year periods Figure 3
Trends in Incidence Rates for Invasive Cervical Cancer for 
CanadianProvinces Rates are standardized according to the 
Canadian population of 1991 and are presented as annual 
averages (per 100,000) for successive five-year periods. 
Source: Statistics Canada.
Trends in Age-Specific Incidence Rates for Invasive Cervical  Cancer inCanada Since 1969 Rates are presented as annual  averages (per 100,000) for successive five-year periods Figure 4
Trends in Age-Specific Incidence Rates for Invasive Cervical 
Cancer inCanada Since 1969 Rates are presented as annual 
averages (per 100,000) for successive five-year periods. 
Source: Statistics Canada.BMC Women's Health 2004, 4:S13 http://www.biomedcentral.com/1472-6874/4/S1/S13
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incidence rates exceed 40 per 100,000 women per year.[2]
Cervical cancer is the most common female neoplasm in
regions such as eastern Africa and the Caribbean, account-
ing for 20% to 30% of all malignancies.[2] The risk in
western Europe and NorthAmerica is considered relatively
low, at fewer than 10 new cases annually per 100,000
women, whereas in high-incidence countries the rates are
10 times greater than this and the cumulative lifetime risk
can approach 10%.
Figure 5 shows cervical cancer incidence and mortality
rates for Canada and selected European countries as pro-
jected for the year 2000. Among the countries chosen for
comparison, only Spain and Switzerland have lower rates
of the disease than Canada. The rate of mortality from cer-
vical cancer in Canada is also lower than in most Euro-
pean countries.
Vulnerable Subgroups
Cervical cancer takes a particularly heavy toll in North
American Native populations, Black women, and His-
panic minorities. Black women in the United States have
about a 50% greater risk of acquiring cervical cancer than
white women but more than twice the risk of dying from
the disease.[4] Ethnic disparities in cervical cancer risk are
not as readily monitored by provincial tumour registries
as they are in the SEER program in the United States. Such
comparisons in Canada rely on occasional surveys.
Among the Canadian Inuit, cervical cancer accounts for
nearly 15% of all female cancers, a relative frequency that
is comparable to that seen in developing countries. The
proportion is even greater among registered Indians in
Saskatchewan, at 29%, which results in an age-standard-
ized rate six times as high as the national average.[5] Also
of concern is the fact that recent immigrant groups to Can-
ada appear to have lower rates of Pap testing and may not
have been reached by the health promotion approaches
used by the provinces to provide Pap smear screening and
appropriate management of precursor lesions. This may
eventually lead to further disparities among ethnic groups
in rates of incidence and mortality.
Survival
An average 26 years of life are lost per woman dying of cer-
vical cancer in Canada. On the basis of this average loss of
life and of the number of deaths each year in Canada, it is
estimated that cervical cancer caused an estimated 11,000
person-years of life lost in 1997.[6]
Figure 6 shows the five-year relative survival rates by time
since cervical cancer diagnosis for Quebec – as represent-
ative of the Canadian experience – for white and Black
women in the United States, and for selected developed
and developing countries with comparable cohort treat-
ment and follow-up periods. The survival rate was highest
among Quebec patients. In North America, patients
whose condition is diagnosed and treated in Quebec have
had better long-term survival than those in the United
States, regardless of ethnicity. The five-year survival rate
for Quebec is also among the highest internationally.
Three main factors influence the magnitude of the survival
rates: (i) the relative proportions of patients with
Annual Age-Standardized Incidence Rates of Invasive Cervical  Cancer (Projection for 2000) for Canada and Selected Euro- pean, Latin American, Caribbean and African Countries Figure 5
Annual Age-Standardized Incidence Rates of Invasive Cervical 
Cancer (Projection for 2000) for Canada and Selected Euro-
pean, Latin American, Caribbean and African Countries. 
Rates are per 100,000 and are standardized according to the 
world population of 1960. Source: Globocan, International 
Agency for Research on Cancer.[2]
Five-Year Relative Survival Rates Following a Diagnosis of  Invasive Cervical Cancer in Canada (Quebec Used as Exam- ple), in the United States (SEER Registries) and in Selected  European and Developing Countries Figure 6
Five-Year Relative Survival Rates Following a Diagnosis of 
Invasive Cervical Cancer in Canada (Quebec Used as Exam-
ple), in the United States (SEER Registries) and in Selected 
European and Developing Countries. Source: Ministère de la 
santé et des services sociaux du Québec; SEER program; 
National Cancer Institute of Canada; International Agency 
for Research on Cancer.BMC Women's Health 2004, 4:S13 http://www.biomedcentral.com/1472-6874/4/S1/S13
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advanced versus early disease stage, (ii) the age
distribution of the cohort of patients, and (iii) access to
the main treatment modalities for cervical cancer (i.e. sur-
gery, radiation therapy and chemotherapy) and their com-
bination integrated into specific treatment protocols.[7]
These three factors, particularly (i) and (iii), are strongly
correlated with socio-economic status. Women of lower
economic means may have their diagnosis delayed, which
may lead to more advanced disease at the time of treat-
ment and consequently to poorer survival. In addition,
they may not be accessing the most modern and effective
cancer treatment protocols.
Ability to pay for health care could be a determinant of the
substantially different survival rates between white and
Black women in the United States and, in specific situa-
tions, between the United States and Canada. A recent
study comparing cancer survival in Detroit and Toronto
found that socio-economic status was associated with cer-
vical cancer survival in Detroit but not in Toronto.
Furthermore, the survival rate among the poorest patients
in Toronto was significantly better than that among the
poorest ones in Detroit for most types of cancer, including
cervical cancer.[8] Nevertheless, even in Canada there is a
noticeable inverse trend in cervical cancer survival as a
function of community income.[9,10]
Risk Factors
The Role of HPV
HPVs are small, double-stranded DNA viruses. As infec-
tious agents, they are highly specific to their respective
hosts. More than 120 different HPV types, derived from
DNA sequence homology, have been catalogued so
far.[11]
Clinical, sub-clinical and latent HPV infections are the
most common sexually transmitted viral diseases
today,[12] with a peak in prevalence among young
women soon after the onset of sexual activity.[12,13]
Latent genital HPV infection can be detected in 5% to
40% of sexually active women of reproductive age.[14] In
most cases, genital HPV infection is transient or intermit-
tent. [15-17]
In epidemiologic studies conducted during the past 10
years, the relative risks (RRs) for the association between
HPV infection (detected by viral DNA testing) and risk of
cervical cancer are high – in some studies greater than
100.[18,19] No other risk factor for cervical neoplasia is of
comparable magnitude. In fact, few associations in cancer
research are as strong as that between HPV and cervical
neoplasia, notable exceptions being the link between
heavy smoking and lung cancer, and chronic hepatitis B
infection and liver carcinoma.[20]
Today, it is well established that infection with the HPV
types associated with high oncogenic risk (types
16,18,31,33,35,39,45,51,52,56,58,59 and 68) is the cen-
tral causal factor in cervical cancer.[14,21] It may even be
a necessary cause of this disease and its precursors.[22,23]
HPV infection should be considered as a risk exposure,
however, since most women who engage in sexual activity
will probably acquire HPV infection over a lifetime. The
vast majority of these infections will be transient, only a
small proportion becoming persistent. A substantial
increase in the risk of CIN exists for women who develop
persistent, long-term infections with oncogenic HPV types
as definedabove.[24,25]
Behavioural and Lifestyle Characteristics
Sexual Behaviour
See "The Role of HPV." Other prominent risk factors are
the role of two measures of sexual activity, namely,
number of sexual partners and age at first intercourse, and
the sexual behaviour of the woman's male
partner(s).[13,26,27]
Smoking
Tobacco smoking has consistently emerged as a risk factor
for cervical cancer.[28] A direct carcinogenic action on the
cervix is conceivable, since nicotine metabolites can be
found in the cervical mucus of smokers.[29] Another
plausible mechanism is suppression of the local immune
response to HPV infection.[12,30] However, a clear
assessment of the association is confounded by other var-
iables. Since smoking is associated with sexual behaviour
it cannot be easily determined whether its association
with cervical neoplasia is genuine or spurious. Studies that
have controlled for the effects of age at first intercourse
and number of sexual partners have generally found an
independent role for tobacco smoking in cervical neopla-
sia, reporting RRs among current versus never smokers in
the range of 1.5–4.5, and evidence of a trend with number
of cigarettes smoked and duration of smoking.[31] On the
other hand, a few studies have failed to find an association
with cigarette smoking.[32,33]
Parity
The number of live births per woman is a consistent risk
factor for cervical cancer. There is a linear trend in the par-
ity-risk association, as seen in large studies in North Amer-
ica and in Latin America.[34,35] It is possible that
multiple pregnancies have a cumulative traumatic or
immunosuppressive effect on the cervix, thereby facilitat-
ing the acquisition of HPV infection.[36] Another non-
mutually exclusive mechanism is the pregnancy-induced
hormonal effect on the cervix, which could affect HPV
genome elements that are responsive to progesterone.[37]BMC Women's Health 2004, 4:S13 http://www.biomedcentral.com/1472-6874/4/S1/S13
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Oral Contraceptive Use
An increased risk of cervical cancer among oral contracep-
tive (OC) users is found mainly among long-term users.
The plausibility of the association rests on the potential
for hormonal effects on HPV-containing cervical cells, as
it has been shown that steroid stimulation may trigger
viral oncogene-related events that could culminate in inte-
gration of the virus into the host's genome.[37] Con-
founding factors are that women who use contraception
tend to be more sexually active than those who do not,
and women using OC are less likely to use barrier meth-
ods of contraception, which have been shown in some
studies to exert a protective effect against CIN [38-40] and
cervical cancer.[25] It is also possible that some associa-
tions may be due to detection bias, since OC users
undergo more frequent gynecological examinations than
non-users, thereby enhancing detection of early
disease.[41]
Dietary Factors
High intake of foods (fruits and vegetables) containing
carotenoids and vitamin C and, to a lesser extent, intake
of vitamins A and E seem to reduce the cervical cancer
risk.[42] The results of dietary surveys have been corrobo-
rated by assays of plasma micronutrient levels. There is
biological plausibility for a protective effect of diet in cer-
vical neoplasia. Carotenoids, tocopherols and ascorbic
acid are potent antioxidants that can quench intracellular
reactive radicals, thus potentially preventing DNA dam-
age. Beta-carotene, in particular, serves as a metabolic pre-
cursor to retinoic acid, which acts by modulating
epithelial cell growth and differentiation. Dietary factors
may also have a role in cervical immunity.[12] Rand-
omized controlled trials of dietary supplementation to
prevent CIN have been conducted or initiated in different
populations.
Human Immunodeficiency Virus Infection
Patients infected with HIV are prone to develop a variety
of infections attributed to their debilitated immune sys-
tem. HIV infection impairs cell-mediated immunity, thus
increasing the risk of HPV-associated diseases, such as
genital warts and malignancies. Latent HPV infection and
SIL are much more common among HIV-infected women
than HIV-negative women from the same popula-
tions.[43,44] HPV and HIV infection seem to interact syn-
ergistically to increase the risk of CIN, with some further
mediation by the degree of immunosuppression.[45]
With the successful adoption of antiretroviral therapy in
the last few years women are surviving longer with their
HIV disease. Little is known, however, about the potential
impact of HIV therapy on the natural history of cervical
neoplasia among HIV-infected women.
Differences Between Histological Types
Squamous and adenocarcinomas present many character-
istics in common; however, there is also evidence to show
that these types may actually have distinct causes despite
being so close together anatomically. Most risk factors are
indeed common to both types. Four main features differ-
entiate their epidemiologic and prevention characteristics:
1. unlike squamous carcinomas, the incidence of adeno-
carcinomas has been increasing in recent years, particu-
larly among younger women in Canada[46] and other
developed nations;[47]
2. HPV 16 is the HPV type most frequently found in squa-
mous carcinomas, whereas HPV 18 is found in more than
half of adenocarcinomas;[48]
3. increased parity is associated with an increased risk of
squamous but not adenocarcinomas;[49]
4. Pap cytology (mentioned below) is not as efficacious in
detecting adenocarcinomas.
The implications of such discrepancies are yet to have an
impact on policy recommendations because current
screening recommendations are based on Pap cytology.
New screening technologies need to take into account the




Primary prevention of cervical cancer can be achieved
through prevention and control of genital HPV infection.
Health promotion strategies geared to a change in sexual
behaviour and targeting all sexually transmitted infections
of public health significance can be effective in preventing
HPV infection.[50,51] Although there is consensus that
symptomatic HPV infection (genital warts) should be
managed by treatment, counselling, and partner notifica-
tion, active case-finding of asymptomatic HPV infection is
currently not recommended as a control measure.
Immunization Against HPV
Two main types of HPV vaccine are currently being devel-
oped: prophylactic vaccines to prevent HPV infection and
associated diseases, and therapeutic vaccines to induce
regression of precancerous lesions or remission of
advanced cervical cancer. Such vaccines are already under
evaluation in phase I and II trials in different popula-
tions.[52] Immunization against HPV may have greatest
value in developing countries, where 80% of the global
burden of cervical cancer occurs each year and where Pap
screening programs are less likely to be effective. At
present, it is difficult to speculate about the direction ofBMC Women's Health 2004, 4:S13 http://www.biomedcentral.com/1472-6874/4/S1/S13
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research in this area. Although the preliminary results
from phase II trials of prophylactic vaccines have been
successful, it will take many years before vaccines can be
assessed as a cervical cancer prevention strategy.[53]
Secondary Prevention
Cervical cancer screening is currently one of the most
active areas of research in cancer prevention (see "Other
Cytology Methods" below). Several new technologies are
under evaluation, and professional and government
groups are considering their contribution in a reassess-
ment of practice guidelines currently being undertaken.
Pap Cytology Screening
Efficacy of Pap Cytology Screening: There have been no
controlled trials of Pap screening efficacy, either rand-
omized or not. The evidence for the efficacy of Pap smear
screening in cervical cancer comes mainly from three
sources: (i) epidemiologic studies reporting a risk of inva-
sive cervical cancer 2–10 times greater among women
who have not been screened and an increased risk with
time since last normal smear or with lower frequency of
screening; (ii) cervical cancer incidence and mortality
rates, which decreased sharply following the introduction
of cytology screening in Scandinavian countries, Canada
and the United States, and did so in proportion to the
intensity of the screening efforts; and (iii) multiple
national and international consensus panels
worldwide.[31]
In spite of its success, cytology has important limitations,
false negative results being the most significant. One
recent meta-analysis indicated that the average sensitivity
of a single Pap test to detect HSIL or cervical cancer was
51%, whereas its specificity was 98%.[54] The solution to
minimizing false-negative errors in cytology is to improve
the quality of smear taking, slide processing and overall
diagnostic performance of cervical cytology. False-nega-
tive diagnoses have important medical, financial and legal
implications.
Canadian Practices
The Canadian Task Force on Preventive Health Care[55]
and a series of consensus workshops [56-59] have pro-
vided uniform national recommendations that have been
reaffirmed on separate occasions by independent prov-
inces or by cancer prevention coalitions across the coun-
try. The Cervical Cancer Prevention Network, created as
an informal association of federal and provincial repre-
sentatives and clinical professional bodies, is the most
important of these coalitions.
In essence, the prevailing guidelines recommend that Pap
screening is to begin at age 18 or at initiation of sexual
activity and to continue annually. After two negative con-
secutive smears, one year apart, screening is to proceed
every three years to age 69. The national workshop recom-
mendations also state that this screening schedule be
implemented in combination with an efficient informa-
tion system allowing rapid case notification and
recall.[56] The empirical basis for the soundness of this set
of management guidelines was recently published.[60]
Other Cytology Methods
There are several automated systems being tested and
marketed. In one of these, liquid-based cytology, the sam-
ple recovered from the cervix is suspended in a cell-pre-
serving solution rather than placed on a glass slide. Excess
blood and inflammatory cells are lysed, and approxi-
mately 50,000 diagnostic cells are randomly transferred
by the equipment as a thin layer onto a glass slide by a
robotic cell processor. The slides are stained and then read
by cytotechnologists. Results from clinical studies have
shown that automated thin-layer slides can improve
detection of atypical cells, precursor lesions and cancer by
producing uniformly cleaner slides free of blood, debris
and cell clumps that interfere with microscopic read-
ing.[27,61] A recent meta-analysis concluded that liquid-
based cytology had superior sensitivity and equivalent
specificity to conventional cytology, and economic mod-
els have indicated that it could lead to lower cost per life-
year saved in the United States.[62]
Computer-assisted scanners map the smear in order to
detect abnormal cells, thereby separating any slides that
contain suspect images for subsequent reading by a cyto-
technologist. A key advantage is the potential to alleviate
the shortage of qualified workers in cytopathology. Com-
parative trials, mostly funded by the private sector, are tak-
ing place in many laboratories in North America and
Europe to answer questions related to screening efficacy
and the cost-effectiveness of automated devices.
Screening by HPV Testing
Since the mid-1990s there has been substantial interest in
the use of standardized HPV DNA testing as a cervical can-
cer screening tool under the premise that it will provide
acceptable diagnostic performance while being more
reproducible and more easily adapted for clinical practice
than conventional Pap cytology. Several studies have
assessed the test's diagnostic performance (for high-risk
types) in a variety of populations, using cross-sectional or
short-term follow-up rather than more extended review of
incidence or mortality rates. [63-69] Lesion definition
varied across studies and included either CIN of all grades
or CIN 2 or 3 or worse lesions.
HPV DNA testing has been shown to have, on average, a
25% greater sensitivity than Pap cytology but somewhat
lower specificity (on average, 10% lower) for detectingBMC Women's Health 2004, 4:S13 http://www.biomedcentral.com/1472-6874/4/S1/S13
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CIN 2/3 or cancer. Screening of women aged 30 or older
tended to improve the specificity considerably, because
viral infections in this age group are less likely to be of a
transient nature than those in younger women. An impor-
tant finding of most studies was that the combination of
cytology and HPV testing attained very high negative pre-
dictive values (approaching 100%), which, at least in the-
ory, could safely permit longer screening intervals, thus
lowering costs. Definitive evidence of efficacy is still
needed from long-term follow-up studies with invasive
cancer as an outcome and from randomized controlled
trials.
One other screening application of HPV testing is in the
secondary triage of equivocal Pap smears. Results from
two large-scale studies have indicated that HPV testing has
greater sensitivity than a repeat Pap test for detecting
hidden HSIL or cancer among women referred because of
an equivocal Pap smear. At the same time it results in
reduced costs in terms of colposcopy referrals.[70,71]
Discussion
Data Limitations
There is a lack of Canadian data on cervical cancer in
women from different ethnic backgrounds, and this pre-
cludes preventive efforts targeted at vulnerable groups.
Most cases of cervical cancer occur because of a false-neg-
ative result of the Pap test, or because the woman did not
receive a Pap test at all or did not receive it often enough.
Well-developed recommendations and guidelines exist as
part of a succession of national consensus reports con-
cerning the implementation and maintenance of cytol-
ogy-based screening programs. However, most Canadian
women do not yet have access to organized, centralized
cervical cancer screening.
Despite the availability of some excellent Canadian sur-
veys of Pap test utilization among women who developed
the invasive form of the disease, we still lack critical infor-
mation concerning the appropriate management of pre-
cursor lesions from audit studies. Various automated
systems aimed at improving the performance of the cytol-
ogy test are currently being tested. Large-scale prospective
studies are still needed to evaluate these systems.
Recommendations
There have been several studies assessing the relative util-
ity of HPV testing in addition to or compared with the Pap
test as a cervical cancer screening tool; these have been
cross-sectional or short-term follow-up investigations,
and no randomized controlled trials have yet been pub-
lished. HPV testing seems to be a promising screening
approach, but definitive evidence of efficacy is still needed
from long-term follow-up studies with invasive cancer as
an outcome and from randomized controlled trials. One
other screening application for HPV testing is in the sec-
ondary triage of equivocal Pap smears. Results from large-
scale studies have indicated that HPV testing has greater
sensitivity than a repeat Pap test for detecting hidden
precursor lesions or cancer among women referred
because of an equivocal Pap smear, while resulting also in
reduced costs for colposcopy referrals. However, taking
into account the totality of the evidence, we still lack
Canadian data to justify augmenting or modifying current
screening programs.
Note
The views expressed in this report do not necessarily rep-
resent the views of the Canadian Population Health Initi-
ative, the Canadian Institute for Health Information or
Health Canada.
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